Please provide your email address to receive an email when new articles are posted on . Retinal implants have a history of challenges, and questions remain about their utility. A bioengineered RPE ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...
ORLANDO -- The PRIMA system combining a subretinal photovoltaic implant and eyeglasses that project near-infrared light to the implant significantly improved vision in patients with geographic atrophy ...
Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...
Over 80% of Patients Demonstrated Meaningful Improvement of Visual Acuity and Were Able to Read Letters, Numbers, and Words Science is a leader in BCI technology and neural engineering. The PRIMA ...
LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...
Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...
While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results